Bisphosphonates in oncology: Breast cancer and beyond

Seminars in Oncology

Volumn 28, Issue 4 SUPPL. 11, 2001, Pages 86-91

  Tripathy, Debu ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; HORMONE;

BONE METASTASIS; BONE MINERAL; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; FLOW CYTOMETRY; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; OSTEOPOROSIS; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0034839828     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2001.25443     Document Type: Conference Paper

References (21)

1. Bisphosphonates induce breast cancer cell death in vitro
2. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases
3. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices
4. Current use of bisphosphonates in oncology
5. Bisphosphonates as anticancer drugs
6. Mechanisms of bone metastasis
7. The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases
8. Bisphosphonates and the prevention of metastasis. First evidences from preclinical and clinical studies
9. Reduction in new metastases in breast cancer with adjuvant clodronate treatment
10. Adjuvant clodronate reduces the incidence of bone metastases in patients with primary operable breast cancer
11. No reduction of bone metastases with adjuvant clodronate treatment in node-positive breast cancer patients
12. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients
13. Prevention and treatment of osteoporosis in women with breast cancer
14. Progressive osteoporosis during androgen deprivation therapy for prostate cancer
15. Androgen deprivation therapy for prostate cancer results in significant loss of bone density
16. British association of surgical oncology guidelines: The management of metastatic bone disease in the United Kingdom
17. Bone marrow micrometastases in breast cancer patients
18. The significance of breast cancer lymph node micrometastases
19. Micrometastases in bone marrow in patients with primary breast cancer: Evaluation as an early predictor of bone metastases
20. Improvement of bone pain, quality of life and survival time of breast cancer patients with metastatic bone disease treated with intravenous ibandronate
21. Cost utility analysis of prophylactic pamidronate for the prevention of skeletal related events in patients with advanced breast cancer